CL2020001461A1 - Inhibidores de dopamina–b–hidroxilasa. - Google Patents

Inhibidores de dopamina–b–hidroxilasa.

Info

Publication number
CL2020001461A1
CL2020001461A1 CL2020001461A CL2020001461A CL2020001461A1 CL 2020001461 A1 CL2020001461 A1 CL 2020001461A1 CL 2020001461 A CL2020001461 A CL 2020001461A CL 2020001461 A CL2020001461 A CL 2020001461A CL 2020001461 A1 CL2020001461 A1 CL 2020001461A1
Authority
CL
Chile
Prior art keywords
compounds
solvates
dopamine
salts
hydroxylase inhibitors
Prior art date
Application number
CL2020001461A
Other languages
English (en)
Spanish (es)
Inventor
Tino Rossi
Laszlo Erno Kiss
Alexander Beliaev
Pedro Nuno Leal Palma
Da Silva Patrício Manuel Vieira Araujo Soares
Rui Pinto
Francisco Cardona
Original Assignee
BIAL PORTELA & C ª S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1720189.8A external-priority patent/GB201720189D0/en
Priority claimed from GBGB1804439.6A external-priority patent/GB201804439D0/en
Application filed by BIAL PORTELA & C ª S A filed Critical BIAL PORTELA & C ª S A
Publication of CL2020001461A1 publication Critical patent/CL2020001461A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2020001461A 2017-12-04 2020-06-01 Inhibidores de dopamina–b–hidroxilasa. CL2020001461A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1720189.8A GB201720189D0 (en) 2017-12-04 2017-12-04 Dopamine-B-hydroxylase inhibitors
GBGB1804439.6A GB201804439D0 (en) 2018-03-20 2018-03-20 Dopamin-b-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
CL2020001461A1 true CL2020001461A1 (es) 2020-10-16

Family

ID=65012066

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001461A CL2020001461A1 (es) 2017-12-04 2020-06-01 Inhibidores de dopamina–b–hidroxilasa.

Country Status (16)

Country Link
US (2) US11434242B2 (cg-RX-API-DMAC10.html)
EP (1) EP3720856A1 (cg-RX-API-DMAC10.html)
JP (1) JP7167155B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200096584A (cg-RX-API-DMAC10.html)
CN (1) CN111479812A (cg-RX-API-DMAC10.html)
AU (1) AU2018379646A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020010216A2 (cg-RX-API-DMAC10.html)
CA (1) CA3082337A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020001461A1 (cg-RX-API-DMAC10.html)
IL (1) IL274550B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020005864A (cg-RX-API-DMAC10.html)
PH (1) PH12020500542A1 (cg-RX-API-DMAC10.html)
RU (1) RU2020121820A (cg-RX-API-DMAC10.html)
SG (1) SG11202004231YA (cg-RX-API-DMAC10.html)
TW (1) TW201925193A (cg-RX-API-DMAC10.html)
WO (1) WO2019112457A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
TW202528310A (zh) * 2023-09-20 2025-07-16 美商深蘋果治療股份有限公司 經取代胺化合物,組合物及使用方法
WO2025161144A1 (zh) * 2024-01-29 2025-08-07 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2449689A1 (fr) 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
US4628059A (en) 1985-10-31 1986-12-09 Smithklein Beckman Corporation Dopamine-β-hydroxylase inhibitors
ES2201104T3 (es) 1994-04-26 2004-03-16 Roche Palo Alto Llc Derivados de benzociclohexilimidazoltiona.
US6482982B1 (en) 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
WO2008085008A1 (en) * 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
NZ583193A (en) 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors

Also Published As

Publication number Publication date
SG11202004231YA (en) 2020-06-29
WO2019112457A1 (en) 2019-06-13
CA3082337A1 (en) 2019-06-13
BR112020010216A2 (pt) 2020-09-15
US20230138795A1 (en) 2023-05-04
US11434242B2 (en) 2022-09-06
US20210171528A1 (en) 2021-06-10
TW201925193A (zh) 2019-07-01
JP7167155B2 (ja) 2022-11-08
PH12020500542A1 (en) 2021-01-25
EP3720856A1 (en) 2020-10-14
MX2020005864A (es) 2020-09-09
IL274550A (en) 2020-06-30
IL274550B2 (en) 2023-06-01
KR20200096584A (ko) 2020-08-12
AU2018379646A1 (en) 2020-06-11
RU2020121820A (ru) 2022-01-10
JP2021505568A (ja) 2021-02-18
CN111479812A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
MX2019003310A (es) Inhibidores de dopamina-b-hidroxilasa.
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
MX2016009013A (es) Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CU20160166A7 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
TR201819805T4 (tr) Flavaglin türevleri̇.
JOP20190163B1 (ar) منشط nrf2
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
UY36123A (es) Derivados de carboxamida
CO2017000211A2 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
BR112021023834A2 (pt) Inibidores de dopamina-b-hidroxilase
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam